Stemline

STML NASDAQ
13.47
-0.35
-2.53%
盘后: 13.47 0 0.00% 17:04 07/19 EDT
开盘
13.81
昨收
13.82
最高
13.81
最低
13.46
成交量
26.99万
成交均量(3M)
47.44万
52周最高
17.85
52周最低
7.82
换手率
0.62%
市值
5.88亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Stemline STML股票价格,Stemline股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
展开 >

最近浏览

名称
价格
涨跌幅